HK-listed China Biopharma (01177.HK) shares rose more than 6% after the company agreed an exclusive licensing deal with AstraZeneca for TQC3721.

Chen Guo, deputy director and chief strategist at East Money Research Institute, said a downturn in the Korean memory-chip sector would not signal the end of the global tech bull and may simply reflect intra-tech rebalancing. He said the move would not imply the end of an A-share re-rating; RMB assets still have room to be re-rated, with particularly large upside for high-quality carbon-based assets in China’s A-share market.

美國總統特朗普的專機已抵達安卡拉，將出席北約峯會。